Compare DFH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | CRVS |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2016 |
| Metric | DFH | CRVS |
|---|---|---|
| Price | $15.22 | $14.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $26.00 | ★ $30.17 |
| AVG Volume (30 Days) | 651.4K | ★ 822.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,322,848,000.00 | N/A |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $40.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $5.03 |
| 52 Week High | $31.10 | $26.95 |
| Indicator | DFH | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.